SEZ6L

Summary

SEZ6L (seizure related 6 homolog like, HGNC:10763) is a protein-coding gene on chromosome 22q12.1, encoding Seizure 6-like protein (Q9BYH1). May contribute to specialized endoplasmic reticulum functions in neurons.

Predicted to be involved in synapse maturation. Predicted to act upstream of or within activation of protein kinase C activity; adult locomotory behavior; and cerebellar Purkinje cell layer development. Predicted to be located in endoplasmic reticulum membrane. Predicted to be active in several cellular components, including glutamatergic synapse; neuronal cell body; and postsynaptic membrane.

Source: NCBI Gene 23544 — RefSeq curated summary.

At a glance

• GWAS associations: 4
• Clinical variants (ClinVar): 197 total — 1 likely-pathogenic
• Phenotypes (HPO): 1
• MANE Select transcript: NM_021115

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:10763
Approved symbol	SEZ6L
Name	seizure related 6 homolog like
Location	22q12.1
Locus type	gene with protein product
Status	Approved
Aliases	SEZ6L1
Ensembl gene	ENSG00000100095
Ensembl biotype	protein_coding
OMIM	607021
Entrez	23544

Gene structure

Transcript identifiers

Ensembl transcripts: 14 — 12 protein_coding, 1 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000248933, ENST00000343706, ENST00000360929, ENST00000402979, ENST00000403121, ENST00000404234, ENST00000483291, ENST00000494013, ENST00000529632, ENST00000629590, ENST00000867853, ENST00000940334, ENST00000940335, ENST00000957709

RefSeq mRNA: 6 — MANE Select: NM_021115 NM_001184773, NM_001184774, NM_001184775, NM_001184776, NM_001184777, NM_021115

CCDS: CCDS13833, CCDS54508, CCDS54509, CCDS54510, CCDS54511, CCDS74837

Canonical transcript exons

ENST00000248933 — 17 exons

Exon	Start	End
ENSE00001150782	26373451	26373483
ENSE00001150792	26375575	26375689
ENSE00001604219	26311768	26311962
ENSE00001661391	26310670	26310836
ENSE00001666301	26313764	26313902
ENSE00001668531	26294292	26294425
ENSE00001701445	26340436	26340632
ENSE00001706165	26305979	26306144
ENSE00001716568	26292406	26293146
ENSE00001745829	26298984	26299169
ENSE00001771464	26347719	26347913
ENSE00001778626	26296888	26297080
ENSE00001930850	26380266	26383596
ENSE00003493616	26351052	26351243
ENSE00003506087	26365372	26365566
ENSE00003628842	26377673	26377775
ENSE00003843605	26169462	26169763

Expression profiles

Bgee: expression breadth ubiquitous, 167 present calls, max score 97.10.

FANTOM5 (CAGE): breadth broad, TPM avg 7.6226 / max 376.9504, expressed in 327 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
191498	4.8119	308
191499	2.6828	241
191496	0.0646	35
191497	0.0632	30

Top tissues by expression

279 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
ganglionic eminence	UBERON:0004023	97.10	gold quality
endothelial cell	CL:0000115	94.13	gold quality
lateral nuclear group of thalamus	UBERON:0002736	93.98	gold quality
ventricular zone	UBERON:0003053	92.91	gold quality
prefrontal cortex	UBERON:0000451	91.81	gold quality
buccal mucosa cell	CL:0002336	91.21	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	90.95	gold quality
CA1 field of hippocampus	UBERON:0003881	90.92	gold quality
cingulate cortex	UBERON:0003027	90.47	gold quality
anterior cingulate cortex	UBERON:0009835	90.44	gold quality
cortical plate	UBERON:0005343	90.02	gold quality
Brodmann (1909) area 9	UBERON:0013540	89.92	gold quality
neocortex	UBERON:0001950	89.19	gold quality
cerebral cortex	UBERON:0000956	89.03	gold quality
Ammon’s horn	UBERON:0001954	88.99	gold quality
hypothalamus	UBERON:0001898	88.98	gold quality
frontal cortex	UBERON:0001870	88.90	gold quality
cerebellar cortex	UBERON:0002129	88.66	gold quality
cerebellar hemisphere	UBERON:0002245	88.60	gold quality
amygdala	UBERON:0001876	88.35	gold quality
cerebellum	UBERON:0002037	88.20	gold quality
right hemisphere of cerebellum	UBERON:0014890	88.09	gold quality
right frontal lobe	UBERON:0002810	88.03	gold quality
islet of Langerhans	UBERON:0000006	87.86	gold quality
substantia nigra pars compacta	UBERON:0001965	86.94	gold quality
middle temporal gyrus	UBERON:0002771	86.28	gold quality
temporal lobe	UBERON:0001871	86.26	gold quality
primary visual cortex	UBERON:0002436	85.79	gold quality
orbitofrontal cortex	UBERON:0004167	85.36	gold quality
telencephalon	UBERON:0001893	85.23	gold quality

Single-cell (SCXA)

Detected in 5 experiment(s), a significant marker in 5.

Experiment	Marker?	Max mean expression
E-HCAD-35	yes	63.92
E-GEOD-84465	yes	26.15
E-GEOD-83139	yes	7.97
E-ANND-3	yes	5.02
E-GEOD-93593	yes	4.34

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

167 targeting SEZ6L, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-3120-5P	100.00	65.56	965
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-4776-3P	100.00	68.73	1340
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-6888-3P	99.97	65.95	1170
HSA-MIR-3688-3P	99.97	72.02	2834
HSA-MIR-8075	99.97	67.20	962
HSA-MIR-548AN	99.97	70.91	2817
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-493-5P	99.96	72.47	2382
HSA-MIR-96-5P	99.95	72.80	2140
HSA-MIR-548J-3P	99.94	72.61	4881
HSA-MIR-6835-3P	99.93	70.49	2904
HSA-MIR-548AE-3P	99.93	72.66	4867

Literature-anchored findings (GeneRIF, showing 4)

• A role of the SEZ6L Met430Ile polymorphic variant in increasing lung cancer risk. (PMID:17804757)
• the addition of SEZ6L improved the performance of the Liverpool Lung Project risk model. (PMID:20424129)
• This is the first demonstration that genetic variants in the SEZ6L gene are associated with bipolar disorder Iin female patients and provides additional compelling evidence for genetic variation at 22q11-13 that influences BD-I risk. (PMID:22920719)
• SEZ6L, HISPPD1, FEZF1, SAMD11 gene variants may be associated with autism spectrum disorder. (PMID:26204995)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	sez6l	ENSDARG00000100594
mus_musculus	Sez6l	ENSMUSG00000058153
rattus_norvegicus	Sez6l	ENSRNOG00000025612

Paralogs (39): CFH (ENSG00000000971), SELE (ENSG00000007908), C8B (ENSG00000021852), C6 (ENSG00000039537), SEZ6 (ENSG00000063015), CFHR2 (ENSG00000080910), APOH (ENSG00000091583), SUSD6 (ENSG00000100647), SRPX (ENSG00000101955), SRPX2 (ENSG00000102359), C7 (ENSG00000112936), C9 (ENSG00000113600), PAPPA2 (ENSG00000116183), CFHR3 (ENSG00000116785), CR2 (ENSG00000117322), CD46 (ENSG00000117335), CSMD2 (ENSG00000121904), C4BPA (ENSG00000123838), C4BPB (ENSG00000123843), CFHR4 (ENSG00000134365), CFHR5 (ENSG00000134389), F13B (ENSG00000143278), SUSD4 (ENSG00000143502), C8A (ENSG00000157131), SUSD3 (ENSG00000157303), CSMD3 (ENSG00000164796), SVEP1 (ENSG00000165124), C2 (ENSG00000166278), SELP (ENSG00000174175), SEZ6L2 (ENSG00000174938), PRF1 (ENSG00000180644), PAPPA (ENSG00000182752), CSMD1 (ENSG00000183117), SELL (ENSG00000188404), CD55 (ENSG00000196352), CR1L (ENSG00000197721), CR1 (ENSG00000203710), CFB (ENSG00000243649), CFHR1 (ENSG00000244414)

Protein

Protein identifiers

Seizure 6-like protein — Q9BYH1 (reviewed: Q9BYH1)

All UniProt accessions (4): B0QYH4, B0QYH5, B7ZLJ8, Q9BYH1

UniProt curated annotations — full annotation on UniProt →

Function. May contribute to specialized endoplasmic reticulum functions in neurons.

Subcellular location. Endoplasmic reticulum membrane.

Tissue specificity. Widely expressed, including adult and fetal brains and lungs. Not expressed in all lung cancer cell lines.

Post-translational modifications. O-glycosylated.

Similarity. Belongs to the SEZ6 family.

Isoforms (7)

UniProt ID	Names	Canonical?
Q9BYH1-1	4	yes
Q9BYH1-2	1
Q9BYH1-3	2
Q9BYH1-4	3
Q9BYH1-5	5
Q9BYH1-6	6
Q9BYH1-7	7

RefSeq proteins (6): NP_001171702, NP_001171703, NP_001171704, NP_001171705, NP_001171706, NP_066938* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000436	Sushi_SCR_CCP_dom	Domain
IPR000859	CUB_dom	Domain
IPR035914	Sperma_CUB_dom_sf	Homologous_superfamily
IPR035976	Sushi/SCR/CCP_sf	Homologous_superfamily
IPR051277	SEZ6_CSMD_C4BPB_Regulators	Family

Pfam: PF00084, PF00431

UniProt features (62 total): glycosylation site 12, disulfide bond 11, domain 8, splice variant 7, strand 7, region of interest 5, sequence variant 4, compositionally biased region 3, topological domain 2, signal peptide 1, chain 1, transmembrane region 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
2YRA	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9BYH1-F1	69.41	0.27

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (11): 281–308, 393–433, 419–448, 567–609, 594–624, 745–787, 773–800, 806–848, 834–865, 873–915, 901–930

Glycosylation sites (12): 49, 311, 328, 350, 435, 458, 474, 514, 576, 618, 674, 742

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 168 (showing top): GOBP_HINDBRAIN_DEVELOPMENT, GOBP_METENCEPHALON_DEVELOPMENT, GOBP_BEHAVIOR, NKX25_02, GOBP_ADULT_BEHAVIOR, MORF_ATRX, GOBP_ADULT_LOCOMOTORY_BEHAVIOR, CHX10_01, GGGTGGRR_PAX4_03, USF_C, NKX61_01, GOBP_CELL_JUNCTION_ORGANIZATION, GOBP_CEREBELLAR_CORTEX_DEVELOPMENT, MODULE_379, GOBP_HEAD_DEVELOPMENT

GO Biological Process (3): adult locomotory behavior (GO:0008344), cerebellar Purkinje cell layer development (GO:0021680), synapse maturation (GO:0060074)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (4): endoplasmic reticulum (GO:0005783), endoplasmic reticulum membrane (GO:0005789), neuronal cell body (GO:0043025), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
locomotory behavior	1
adult behavior	1
cerebellar cortex development	1
anatomical structure development	1
nervous system development	1
developmental maturation	1
synapse organization	1
binding	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1
organelle membrane	1
nuclear outer membrane-endoplasmic reticulum membrane network	1
endoplasmic reticulum subcompartment	1
somatodendritic compartment	1
cell body	1
cellular anatomical structure	1

Protein interactions and networks

STRING

2429 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SEZ6L	MYO18B	Q8IUG5	924
SEZ6L	GRK3	P35626	816
SEZ6L	BACE2	Q9Y5Z0	598
SEZ6L	RNF222	A6NCQ9	574
SEZ6L	MYO18A	Q92614	552
SEZ6L	GCSAML	Q5JQS6	531
SEZ6L	ARVCF	O00192	495
SEZ6L	FAM174A	Q8TBP5	475
SEZ6L	SRRD	Q9UH36	470
SEZ6L	TANGO2	Q6ICL3	456
SEZ6L	TNRC18	O15417	440
SEZ6L	GALNT18	Q6P9A2	430
SEZ6L	CACHD1	Q5VU97	430
SEZ6L	OSBPL6	Q9BZF3	429
SEZ6L	BACE1	P56817	426

IntAct

4 interactions, top by confidence:

A	B	Type	Score
APP	SEZ6L	psi-mi:“MI:0915”(physical association)	0.370
SEZ6L	PTPRD	psi-mi:“MI:0914”(association)	0.350
RSPH1	SEZ6L	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (10): SEZ6L (Two-hybrid), UBQLN1 (Two-hybrid), GPRASP2 (Two-hybrid), UBQLN2 (Two-hybrid), SEZ6L (Affinity Capture-MS), SNX17 (Affinity Capture-MS), MYADM (Affinity Capture-MS), PTPRS (Affinity Capture-MS), PTPRD (Affinity Capture-MS), SEZ6L (Two-hybrid)

ESM2 similar proteins: A5D8T8, O35217, O75078, O75882, O75900, O88272, O88507, O88676, O95633, P08887, P0C7M8, P0C7M9, P26992, P78539, Q00961, Q01098, Q08406, Q0ZCA7, Q14957, Q1LZB9, Q2TBM7, Q4V7F2, Q5EA46, Q5VV63, Q63769, Q642A6, Q6A051, Q6IA17, Q6P1D5, Q6PCB0, Q6UXF7, Q71DR4, Q7TNS7, Q7TSQ1, Q8NCF0, Q8R2Z5, Q8R366, Q91XD7, Q96FT7, Q96HD1

Diamond homologs: A0A182C2Z2, A0JNA2, B3EX01, E7FEC4, O08569, O19124, O57254, O62685, O62837, O88174, P08174, P0DTN2, P15529, P21115, P24083, P24084, P36980, P49457, P79138, P81475, Q01227, Q07968, Q28085, Q29RN8, Q4V9Z5, Q53EL9, Q5R4D0, Q5R8M2, Q5VX71, Q60736, Q63515, Q6AX42, Q6P1D5, Q6UXD5, Q7TSK2, Q7Z408, Q8BH32, Q9BYH1, Q9JF44, Q9W332

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

197 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	1
Uncertain significance	163
Likely benign	12
Benign	7

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
4819298	NM_021115.5(SEZ6L):c.2574G>A (p.Trp858Ter)	Likely pathogenic

SpliceAI

2950 predictions. Top by Δscore:

Variant	Effect	Δscore
22:26169759:GCGAG:G	donor_gain	1.0000
22:26169760:CGAG:C	donor_gain	1.0000
22:26169761:GAG:G	donor_gain	1.0000
22:26169761:GAGG:G	donor_gain	1.0000
22:26169762:AG:A	donor_gain	1.0000
22:26169762:AGGTA:A	donor_loss	1.0000
22:26169763:GG:G	donor_gain	1.0000
22:26169763:GGTA:G	donor_loss	1.0000
22:26169764:G:GG	donor_gain	1.0000
22:26169764:GTAA:G	donor_loss	1.0000
22:26292403:A:AG	acceptor_gain	1.0000
22:26292403:AAGAT:A	acceptor_gain	1.0000
22:26292404:A:G	acceptor_gain	1.0000
22:26292405:GAT:G	acceptor_gain	1.0000
22:26294437:A:T	donor_gain	1.0000
22:26294470:G:GT	donor_gain	1.0000
22:26296875:T:TA	acceptor_gain	1.0000
22:26296884:CCA:C	acceptor_loss	1.0000
22:26296886:A:AG	acceptor_gain	1.0000
22:26296886:A:C	acceptor_loss	1.0000
22:26296887:G:GG	acceptor_gain	1.0000
22:26297044:G:GT	donor_gain	1.0000
22:26297079:GG:G	donor_gain	1.0000
22:26297080:GG:G	donor_gain	1.0000
22:26310664:T:A	acceptor_gain	1.0000
22:26310833:GAAG:G	donor_gain	1.0000
22:26310834:AAGGT:A	donor_loss	1.0000
22:26310835:AG:A	donor_gain	1.0000
22:26310835:AGG:A	donor_loss	1.0000
22:26310836:GG:G	donor_gain	1.0000

AlphaMissense

6654 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
22:26299144:G:C	W441C	1.000
22:26299144:G:T	W441C	1.000
22:26311867:G:A	C594Y	1.000
22:26311911:T:A	C609S	1.000
22:26311911:T:C	C609R	1.000
22:26311912:G:C	C609S	1.000
22:26311935:T:A	W617R	1.000
22:26311935:T:C	W617R	1.000
22:26311937:G:C	W617C	1.000
22:26311937:G:T	W617C	1.000
22:26311956:T:A	C624S	1.000
22:26311956:T:C	C624R	1.000
22:26311957:G:C	C624S	1.000
22:26313855:G:C	W656C	1.000
22:26313855:G:T	W656C	1.000
22:26347767:G:A	G754D	1.000
22:26347817:T:G	Y771D	1.000
22:26347823:T:A	C773S	1.000
22:26347823:T:C	C773R	1.000
22:26347824:G:A	C773Y	1.000
22:26347824:G:C	C773S	1.000
22:26347824:G:T	C773F	1.000
22:26347825:T:G	C773W	1.000
22:26347865:T:A	C787S	1.000
22:26347865:T:C	C787R	1.000
22:26347866:G:A	C787Y	1.000
22:26347866:G:C	C787S	1.000
22:26347867:C:G	C787W	1.000
22:26347883:T:A	W793R	1.000
22:26347883:T:C	W793R	1.000

dbSNP variants (sampled 300 via entrez): RS1000000479 (22:26309904 A>G), RS1000024155 (22:26295911 A>G,T), RS1000079757 (22:26280915 A>C,G), RS1000080194 (22:26288316 A>G), RS1000086169 (22:26172235 A>G), RS1000095760 (22:26205703 C>T), RS1000114215 (22:26233373 G>A,T), RS1000163137 (22:26204318 G>A,T), RS1000172300 (22:26340078 C>G), RS1000192114 (22:26331183 C>T), RS1000194992 (22:26265638 C>A), RS1000214417 (22:26236174 G>A,C), RS1000223706 (22:26188057 A>T), RS1000248538 (22:26239269 G>A,C), RS1000248618 (22:26236441 T>C)

Disease associations

OMIM: gene MIM:607021 | disease phenotypes: MIM:610425, MIM:209850

GenCC curated gene-disease

Mondo (3): prostate cancer (MONDO:0008315), cataract 23 (MONDO:0012489), autism (MONDO:0005260)

Orphanet (2): Familial prostate cancer (Orphanet:1331), Early onset non-syndromic cataract (Orphanet:91492)

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0000717	Autism

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST001208_14	Insulin resistance/response	6.000000e-06
GCST001621_27	Airflow obstruction	5.000000e-06
GCST002590_5	Vascular brain injury	8.000000e-06
GCST002938_28	Copper levels	5.000000e-06

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0003892	pulmonary function measurement
EFO:0006800	vascular brain injury measurement

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D001321	Autistic Disorder	F03.625.164.113.500
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

27 total (human), top 27 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Nickel	decreases expression	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
Tretinoin	increases expression	2
sodium arsenate	decreases expression	1
sodium arsenite	affects methylation	1
cobaltous chloride	decreases expression	1
tetrabromobisphenol A	increases expression	1
benzo(e)pyrene	decreases methylation	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
MT19c compound	decreases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Vorinostat	decreases expression	1
Atrazine	increases expression	1
Benzo(a)pyrene	increases methylation	1
Copper	affects cotreatment, decreases expression	1
Doxorubicin	decreases expression	1
Fluorouracil	affects reaction, decreases expression	1
Formaldehyde	decreases expression	1
Lead	affects splicing	1
Methapyrilene	decreases methylation	1
Rotenone	increases expression	1
Silicon Dioxide	decreases expression	1
Triclosan	decreases expression	1
Valproic Acid	increases expression	1
Zinc	decreases expression	1
Aflatoxin B1	decreases methylation	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer